The first precision biology–based telehealth service designed to improve GLP-1 tolerability, safety, and effectiveness is now available as a self-pay option within employer populations.

Mountain View, CA  — Digbi Health today announced the expansion of its nationally deployed employer-sponsored GLP-1 telemedicine program to include a new self-pay access and fulfillment pathway for employees and eligible family members who may not have access to GLP-1 weight-loss medications through their employer-sponsored programs.

This expansion makes the first precision biology–powered telehealth service accessible to a broader population within employer ecosystems.

Digbi Health’s GLP-1 Program is a comprehensive, employer-backed telemedicine solution—now expanded with a self-pay option—that streamlines every step of the GLP-1 journey for employees and their eligible family members, from clinical evaluation to prescription to fulfillment.

Digbi Health’s Precision GLP-1 Program includes:

1. Clinically supervised access to FDA-approved GLP-1 medications, including Wegovy®, Ozempic®, and Zepbound®, with access to an introductory cash price of $199 per month for Ozempic® and Wegovy® injection pens for Digbi self-pay users, along with clear, transparent pricing and no hidden fees.
2. Flexible fulfillment options, including in-pharmacy pickup for Wegovy® or Zepbound® pens and convenient home delivery for Zepbound® vial formulations.
3. Virtual consultations with licensed clinicians who determine eligibility, order all required labs (included at no cost), and write prescriptions when medically appropriate.
4. Continuous clinical oversight to track progress, manage side effects, and adjust titration or care plans to improve tolerability and adherence.
5. Precision biology diagnostics, including DNA testing, gut microbiome testing, and continuous glucose monitoring to identify insulin resistance, glucose dysregulation, and biological factors that influence GLP-1 effectiveness.
6. AI-powered nutritional guidance to optimize protein intake, reduce GI symptoms, improve gut health, and support natural GLP-1 production.
7. A personalized, member-first experience that prioritizes safety, tolerability, and metabolic effectiveness—not just access to medication.

The Biology Problem: Why Many GLP-1 Users Quit or Don’t Respond

While GLP-1 medications such as Wegovy®, Ozempic®, and Zepbound® have reshaped metabolic health, real-world outcomes remain inconsistent:

• 30–40% of users experience significant GI-related adverse effects

• Many experience hair loss, muscle loss, constipation, and nutrient deficiencies

• Nearly 25% lose less than 5% of their body weight, driven by insulin resistance, impaired glucose control, or microbiome-mediated variability in drug response.

These issues drive early discontinuation—creating avoidable waste and limiting long-term outcomes.

Digbi Health’s precision-biology approach fills these gaps by addressing the underlying metabolic drivers of GLP-1 tolerability and effectiveness.

Every Digbi-covered and Digbi self-pay member receives a fully integrated, biology-driven care model, including:

• Clinical prescribing and titration pathways for Wegovy®, Ozempic®, and Zepbound®

• DNA analysis for metabolic risk, appetite regulation, weight regain risk, and drug responsiveness

• Gut microbiome testing to identify inflammation, digestive vulnerabilities, and GLP-1 degradation pathways

• Continuous glucose monitoring (CGM) to personalize glucose control and predict medication responsiveness

• AI-driven meal scoring and nutrition coaching informed by glucose, microbiome, and genetic insights to reduce side effects

• GI care and food-as-medicine interventions to enhance natural GLP-1 production and improve drug tolerability

“GLP-1 tolerability and effectiveness depend heavily on biology. By expanding self-pay access to employees and their families, we ensure that more people receive safe, personalized care—guided by genetics, the microbiome, and glucose data—to improve outcomes and reduce avoidable discontinuation.”
— Ranjan Sinha, Founder and CEO,  Digbi Health